STEROIDE UND PROTEINKONJUGATE DAFÜR

European patent · EP3538539 · In force

Register entry

Publication number
EP3538539
Application number
EP17801239
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 7, 2017
Published
Sep 18, 2019
Granted
Aug 27, 2025
Protection ends at the latest
Nov 6, 2037
Next annual fee due
Nov 30, 2026
IPC classes
C07J 41/00 (2006.01)
C07J 71/00 (2006.01)
A61K 47/68 (2017.01)
A61K 31/566 (2006.01)
A61K 31/58 (2006.01)
A61K 47/69 (2017.01)
A61P 29/00 (2006.01)
Priority
US 201662419365 P 08.11.2016
US 201762508317 P 18.05.2017
PCT application
PCT/US2017/060434 07.11.2017
PCT publication
WO2018/089373 17.05.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 8, 2026

    Change

    Published in Swissreg on 08.07.2026

  2. Dec 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.11.2025 → 30.11.2026

    Published in Swissreg on 01.12.2025

  3. Oct 1, 2025

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 01.10.2025

  4. Aug 27, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 27.08.2025

Parties

Holder

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road, Tarrytown, NY 10591, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

HAN, Amy

Tarrytown, New York 10591-6707, US

OLSON, William

Tarrytown, New York 10591-6707, US

MURPHY J., Andrew

Tarrytown, New York 10591-6707, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.